Metabolomic Diagnostics is already preparing for broadening its product portfolio to include risk stratification for Preterm Birth. In collaboration with world-leading metabolomics researchers in New Zealand and clinicians in Brazil, Metabolomic Diagnostics started in Q3/2016 the product development process for a Preterm Birth risk stratification product to complement Metabolomic Diagnostics preeclampsia offering. The discovery part of that project was funded by the Gates Foundation.